My watch list  


Systematic (IUPAC) name
CAS number 3930-20-9
ATC code C07AA07
PubChem 5253
Chemical data
Formula C12H20N2O3S 
Mol. mass 272.3624 g/mol
Pharmacokinetic data
Bioavailability >95%
Metabolism Not metabolised
Half life 12 hours
Excretion Renal
Lactic (In lactating females)
Therapeutic considerations
Pregnancy cat.


Legal status

Prescription only

Routes oral

Sotalol (trade names Betapace and Betapace AF, Berlex Laboratories) is a drug used in individuals with rhythm disturbances (cardiac arrhythmias) of the heart, and to treat hypertension in some individuals.


It falls into the class III antiarrhythmic agents because it inhibits the inward potassium ion channels in the heart. It is also a beta blocker because of its primary action on the β-adrenergic receptors in the heart.

By blocking the potassium channels, sotalol prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity.

It also slows atrioventricular (AV) nodal conduction (beta-blocking effect).

Sotalol is a racemic mix of D and L enantiomers. The L isomer is a beta blocker.

Sotalol is not selected for its beta-blocking ability, but rather for its Class III (potassium blocking) properties.


Sotalol is used to treat ventricular tachycardias as well as atrial fibrillation. Betapace AF is specifically labeled for atrial fibrillation.

Some evidence suggests that sotalol should be avoided in the setting of decreased ejection fraction due to heart attack.[1]

See also

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sotalol". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE